Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors
Sunita M. C. De Sousa, John Baranoff, R. Louise Rushworth, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 105, Iss. 3, pp. e108-e118
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
Stephan Petersenn, Maria Fleseriu, Felipe F. Casanueva, et al.
Nature Reviews Endocrinology (2023) Vol. 19, Iss. 12, pp. 722-740
Open Access | Times Cited: 151
Diagnosis and Treatment of Acromegaly: An Update
Nazanin Ershadinia, Nicholas A. Tritos
Mayo Clinic Proceedings (2022) Vol. 97, Iss. 2, pp. 333-346
Open Access | Times Cited: 75
Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors
Renato Cozzi, Maria Rosaria Ambrosio, Roberto Attanasio, et al.
European Journal of Endocrinology (2022) Vol. 186, Iss. 3, pp. P1-P33
Open Access | Times Cited: 49
Quality of life in Prolactinoma: A systematic review
Mendel Castle‐Kirszbaum, Nienke R. Biermasz, Jeremy Kam, et al.
Pituitary (2024) Vol. 27, Iss. 3, pp. 239-247
Open Access | Times Cited: 11
Treatment of Prolactinoma
Warrick J. Inder, Christina Jang
Medicina (2022) Vol. 58, Iss. 8, pp. 1095-1095
Open Access | Times Cited: 34
Update in Pathogenesis, Diagnosis, and Therapy of Prolactinoma
Noriaki Fukuhara, Mitsuru Nishiyama, Yasumasa Iwasaki
Cancers (2022) Vol. 14, Iss. 15, pp. 3604-3604
Open Access | Times Cited: 29
Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment
Łukasz Działach, Joanna Sobolewska, Zuzanna Żak, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 7
Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study
Mussa Almalki, Moayad A Alsuraikh, Eyad Almalki, et al.
Pituitary (2024) Vol. 27, Iss. 2, pp. 197-203
Closed Access | Times Cited: 7
Gender-specific prolactin thresholds to determine prolactinoma size: a novel Bayesian approach and its clinical utility
Markus Huber, Markus M. Luedi, Gerrit Alexander Schubert, et al.
Frontiers in Surgery (2024) Vol. 11
Open Access | Times Cited: 6
Disturbi del controllo degli impulsi in pazienti con tumori ipofisari trattati con dopamino-agonisti
Giulia Cristilli, Benedetta Gardini, Irene Comune, et al.
L Endocrinologo (2025)
Closed Access
A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies
Jennifer Mann, Yves Starreveld, Jay Riva-Cambrin, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1089-1089
Open Access
Gender differences in prolactin thresholds and their association with lactotroph adenoma invasiveness for potential treatment considerations
Lukas Andereggen, Emanuel Christ, Andrea Stieger, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Dysfunctional sexual behaviors: definition, clinical contexts, neurobiological profiles and treatments
Perrotta Giulio
International Journal of Sexual and Reproductive Health Care (2020), pp. 061-069
Open Access | Times Cited: 38
Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management?
Sunita M. C. De Sousa
Endocrine Oncology (2022) Vol. 2, Iss. 1, pp. R31-R50
Open Access | Times Cited: 19
How to manage intolerance to dopamine agonist in patients with prolactinoma
Matheo Augusto Morandi Stumpf, Felipe Moura Maia Pinheiro, Gilberto Ochman Silva, et al.
Pituitary (2023) Vol. 26, Iss. 2, pp. 187-196
Closed Access | Times Cited: 11
Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review
Ross Hamblin, Niki Karavitaki
Archives of Medical Research (2023) Vol. 54, Iss. 8, pp. 102910-102910
Open Access | Times Cited: 9
Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern
Sunita M. C. De Sousa, Alistair Jukes, Nicholas G. Candy, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 5, pp. 314-314
Open Access | Times Cited: 3
Hypersexuality in neurological disorders: A systematic review
Natalie Tayim, Pedro Barbosa, Jalesh N. Panicker
BMJ Mental Health (2024) Vol. 27, Iss. 1, pp. e300998-e300998
Open Access | Times Cited: 3
Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas
José Miguel Hinojosa‐Amaya, Nathaniel Johnson, Christina Gonzalez‐Torres, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 27
Molecular Imaging of Pituitary Tumors
Daniel Gillett, James MacFarlane, Waiel Bashari, et al.
Seminars in Nuclear Medicine (2023) Vol. 53, Iss. 4, pp. 530-538
Closed Access | Times Cited: 8
Advances in the Medical Treatment of Cushing Disease
Nicholas A. Tritos, Beverly M. K. Biller
Endocrinology and Metabolism Clinics of North America (2020) Vol. 49, Iss. 3, pp. 401-412
Closed Access | Times Cited: 21
11C-methionine PET aids localization of microprolactinomas in patients with intolerance or resistance to dopamine agonist therapy
Waiel Bashari, Merel van der Meulen, James MacFarlane, et al.
Pituitary (2022) Vol. 25, Iss. 4, pp. 573-586
Open Access | Times Cited: 13
Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy
Anahid Hamidianjahromi, Nicholas A. Tritos
Reviews in Endocrine and Metabolic Disorders (2022)
Closed Access | Times Cited: 13
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study
Guglielmo Beccuti, Federica Guaraldi, Gianluca Natta, et al.
Journal of Endocrinological Investigation (2020) Vol. 44, Iss. 8, pp. 1699-1706
Open Access | Times Cited: 20
Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas
Ji Yong Park, Wonsuk Choi, A Ram Hong, et al.
Pituitary (2021) Vol. 24, Iss. 6, pp. 955-963
Closed Access | Times Cited: 15
Page 1 - Next Page

Scroll to top